Ruff, Christian T.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 6,382

Edoxaban versus warfarin in patients with atrial fibrillation

Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 5,164

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 5,051

Genetic drivers of heterogeneity in type 2 diabetes pathophysiology

Suzuki, K., Hatzikotoulas, K., Southam, L., Taylor, H. J., Yin, X., Lorenz, K. M., Mandla, R., Huerta-Chagoya, A., Melloni, G. E. M., Kanoni, S., et al. (2024) · Nature

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 606

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 557

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Ruff, C. T., Giugliano, R. P., Braunwald, E., Morrow, D. A., Murphy, S. A., Kuder, J. F., Deenadayalu, N., Jarolim, P., Betcher, J., Shi, M., et al. (2015) · The Lancet

Atrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis Mechanisms

Cited by 405

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 359

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 265

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis

Marston, N. A., Giugliano, R. P., Melloni, G. E. M., Park, J.-G., Morrill, V., Blazing, M. A., Ference, B., Stein, E., Stroes, E. S., Braunwald, E., et al. (2022) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 262

Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial

Ruff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022) · Nature Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 102

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 94

Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis

Small, A. M., Melloni, G. E. M., Kamanu, F. K., Bergmark, B. A., Bonaca, M. P., O’Donoghue, M. L., Giugliano, R. P., Scirica, B. M., Bhatt, D., Antman, E. M., et al. (2024) · JAMA Cardiology

Cardiac Valve Diseases and TreatmentsGenetic Associations and Epidemiology

Cited by 23

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction

Small, A. M., Yang, T.-Y., Itoh, S., Thériault, S., Dufresne, L., Kurosawa, R., Komuro, I., Matsuda, K., Vy, H. M. T., Farber-Eger, E. H., et al. (2026) · Nature Genetics

Cardiac Valve Diseases and TreatmentsGenetic Associations and Epidemiology

Cited by 18

Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world

Ruff, C. T., Giugliano, R. P., Antman, E. M., Murphy, S. A., Lotan, C., Heuer, H., Merkely, B., Baracioli, L., Schersten, F., Seabro-Gomes, R., et al. (2012) · International Journal of Cardiology

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 14

Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: systematic review and meta-analysis

Bilal, A., Yi, F., Gonzalez, G. R., Ali, M., Im, K., Ruff, C. T., Thethi, T. K., & Pratley, R. E. (2024) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 14

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab

Korthauer, L. E., Giugliano, R. P., Guo, J., Sabatine, M. S., Sever, P., Keech, A., Atar, D., Kurtz, C., Ruff, C. T., Mach, F., et al. (2022) · PLOS ONE

Lipoproteins and Cardiovascular HealthAlzheimer's disease research and treatments

Cited by 11